Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669034 | 0.79 | KCNQ4 (0.47) | MEN1KMT2ARIPK1L3MBTL1 | |
| SCHEMBL7609127 | 0.70 | ALDH1A1 (0.50) | TDP1TAS2R14RIPK1ALDH1A1L3MBTL1 | |
| SCHEMBL7965956 | 0.69 | SMN1; SMN2 (0.46) | TDP1RIPK1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5542200 | 0.68 | KCNA5 (0.50) | TDP1MEN1KMT2ATAS2R14RAB9A | |
| SCHEMBL2441712 | 0.67 | MEP1B (0.49) | TDP1MEN1KMT2ATAS2R14RAB9A | |
| SCHEMBL1669089 | 0.67 | LOXL2 (0.43) | RIPK1ALDH1A1BCL2A1 | |
| SCHEMBL17542506 | 0.67 | HDAC3 (0.47) | TDP1TAS2R14RIPK1 | |
| SCHEMBL5537402 | 0.67 | PYCR1 (0.47) | TDP1MEN1KMT2ARIPK1ALDH1A1 | |
| SCHEMBL28842786 | 0.67 | ADH1B (0.47) | TDP1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL7088444 | 0.67 | TDP1 (0.41) | TDP1TAS2R14RIPK1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245241-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | TDP1 8/4885MEN1 4650/4885KMT2A 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.